Glaucoma market shows growing patient population, acceptance of new treatments
Click Here to Manage Email Alerts
SAN FRANCISCO — The current glaucoma treatment landscape features a growing patient population, new market segments and acceptance of novel treatments, according to a speaker here.
“We know drugs have been working well. We have lots of drug options, and we’re getting new ones still,” Kristin H. Ingenito, MBA, said at Glaucoma 360 New Horizons Forum. “We’re also now adding new procedures to the mix, and those are seeing success. This is a really good, exciting space to be in.”
Reimbursement still poses a challenge to the glaucoma therapeutic market, Ingenito said, and demand is growing for “flexible and varying” treatment options. According to Market Scope data, of the $6.1 billion in the global glaucoma product market in 2021, pharmaceuticals accounted for 80%, devices for 13% and diagnostic equipment for 7%, she said. Of the market share accounted for by devices, 6% was accounted for by MIGS, 2% by canal surgery devices, 2% by tube shunts, 2% by lasers and 1% by other devices.
The market also has “lots of room” for artificial intelligence diagnostic tools, Ingenito said.
“If we can expand access to care and use AI to help other care providers with screening and get those patients into the mix faster, we can understand that space and we’re better addressing our patients,” she said.
Collapse
Ingenito KH. The pressure’s on: An inside look at the glaucoma treatment market. Presented at: Glaucoma 360 New Horizons Forum; Feb. 11, 2022; San Francisco.
Read more about
Click Here to Manage Email Alerts